Japan Animal Referral Medical Center Co., Ltd.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Japan Animal Referral Medical Center Co., Ltd. owes ¥0.56 for every ¥1 it owns. Net profit rose 60% in the year to Mar 2026, and grew 30% a year on average over 3 years.
Compared with Consumer Cyclical companies in Japan · latest annual results Mar 2026.
P/E ratio
14.2Investors pay ¥14.2 for every ¥1 of Japan Animal Referral Medical Center Co., Ltd.'s yearly profit, higher than 50% of Consumer Cyclical companies in Japan.
P/B ratio
2.56The share price is 2.56 times Japan Animal Referral Medical Center Co., Ltd.'s book value per share, higher than 81% of Consumer Cyclical companies in Japan.
Market cap
¥12.7 BThe total market value of all of Japan Animal Referral Medical Center Co., Ltd.'s shares at today's price (share price × number of shares), smaller than 59% of Consumer Cyclical companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥5.0 BWhat Japan Animal Referral Medical Center Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥383.59Net worth divided by the number of shares. The share price of ¥981.00 is 2.6 times this, which is the P/B above.
Return on equity (ROE)
19.4%Japan Animal Referral Medical Center Co., Ltd. earned 19.4% on its shareholders' money over the last year, higher than 88% of Consumer Cyclical companies in Japan.
Owes vs Owns
0.56×Japan Animal Referral Medical Center Co., Ltd. owes ¥0.56 for every ¥1 it owns (moderate), higher than 64% of Consumer Cyclical companies in Japan.
Dividend yield
1.33%Japan Animal Referral Medical Center Co., Ltd. pays 1.33% of its share price as dividends a year, lower than 81% of dividend-paying Consumer Cyclical companies in Japan.
Revenue growth
+17%Revenue rose 17% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Profit growth
+60%Net profit rose 60% in the year to Mar 2026, and grew 30% a year on average over 3 years.
Profit margin
13.5%Japan Animal Referral Medical Center Co., Ltd. keeps ¥13 of every ¥100 of revenue as net profit.
Cash quality
1.7×Cash from Japan Animal Referral Medical Center Co., Ltd.'s business was 1.7× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
31.8×Japan Animal Referral Medical Center Co., Ltd.'s operating profit covered its interest costs 31.8 times in the year to Mar 2026.
Cash vs debt
Net debtJapan Animal Referral Medical Center Co., Ltd. had ¥3.6 B more debt than cash (net debt) at Mar 2026.
Questions
What is Japan Animal Referral Medical Center Co., Ltd.'s P/E ratio?
Investors pay ¥14.2 for every ¥1 of Japan Animal Referral Medical Center Co., Ltd.'s yearly profit, higher than 50% of Consumer Cyclical companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Japan Animal Referral Medical Center Co., Ltd.: ¥12.7 B ÷ ¥5.0 B (30 Jun 2026) = 2.6.
What is Japan Animal Referral Medical Center Co., Ltd.'s return on equity?
Japan Animal Referral Medical Center Co., Ltd. earned 19.4% on its shareholders' money over the last year, higher than 88% of Consumer Cyclical companies in Japan.
How much does Japan Animal Referral Medical Center Co., Ltd. owe compared with what it owns?
Japan Animal Referral Medical Center Co., Ltd. owes ¥0.56 for every ¥1 it owns (moderate), higher than 64% of Consumer Cyclical companies in Japan.
Does Japan Animal Referral Medical Center Co., Ltd. pay a dividend?
Yes. Japan Animal Referral Medical Center Co., Ltd. pays 1.33% of its share price as dividends a year, lower than 81% of dividend-paying Consumer Cyclical companies in Japan.
Is Japan Animal Referral Medical Center Co., Ltd.'s revenue growing?
Revenue rose 17% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.